Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor-specific human B-cell antibody discovery study
NL-OMON47403Recruiting
- Sponsor
- AIMM Therapeutics
- Start
- May 2013
- Countries
- 1
01
Overview
Open-label trial in cancer, melanoma, leukemia and 3 more, sponsored by AIMM Therapeutics. Primary endpoint: Identification and production of tumor-specific monoclonal antibodies. Started May 2013; status: recruiting.
02
Conditions
cancermelanomaleukemialymphomapancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON47403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47403.